Abbott Laboratories Form 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories reported unaudited results for the three months ended March 31, 2022. The company operates through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. Abbott had approximately 1.751 billion common shares outstanding at March 31, 2022.
Financial Results and Key Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $11.895 billion | $10.456 billion | 13.8% increase |
| Operating earnings | $2.912 billion | $2.109 billion | 38.0% increase |
| Net earnings | $2.447 billion | $1.793 billion | 36.5% increase |
| Diluted EPS | $1.37 | $1.00 | 37.0% increase |
| Gross margin | 53.8% | 53.0% | 80 basis-point increase |
| Operating margin | 24.5% | 20.2% | Approx. 430 basis-point increase |
| Net margin | 20.6% | 17.2% | Approx. 340 basis-point increase |
| Cash flow from operations | $2.065 billion | $2.637 billion | $572 million decrease |
- Sales excluding foreign exchange increased 17.5%; foreign exchange reduced reported sales by 3.7%. Excluding COVID-19 testing sales and foreign exchange, sales increased 7.7%.
- COVID-19 testing-related sales were approximately $3.3 billion, compared with $2.2 billion in the prior-year quarter.
- Segment sales were $1.147 billion for Established Pharmaceuticals, $1.894 billion for Nutritionals, $5.286 billion for Diagnostics, and $3.565 billion for Medical Devices.
- Cash and cash equivalents were $7.675 billion at March 31, 2022, down from $9.799 billion at December 31, 2021. Working capital was approximately $10.8 billion.
- Total debt was approximately $17.1 billion, consisting primarily of $17.086 billion of long-term debt and $4 million of current debt. Abbott repaid $750 million of notes at maturity during the quarter.
- Abbott had $5 billion of available credit lines expiring in 2025 and maintained investment-grade debt ratings of AA- from Standard & Poor’s and A1 from Moody’s.
- Capital expenditures were $321 million. Dividends paid were $832 million, and share repurchases were $2.307 billion.
- Abbott repurchased 17.3 million shares for approximately $2.1 billion. Approximately $3.981 billion remained available under the 2021 repurchase authorization.
- The quarterly dividend declared was $0.47 per share, compared with $0.45 per share in Q1 2021.
Material Changes Versus the Prior Comparable Period
- Diagnostics sales increased 31.7% as reported and 35.1% excluding foreign exchange, primarily because of higher demand for rapid COVID-19 tests.
- Medical Devices sales increased 7.4% as reported and 11.5% excluding foreign exchange. FreeStyle Libre sales increased 26.2% excluding foreign exchange to $995 million.
- Established Pharmaceutical Products sales increased 7.1% as reported and 13.4% excluding foreign exchange.
- Nutritional Products sales decreased 7.0% as reported and 4.4% excluding foreign exchange. U.S. Pediatric Nutritionals declined 33.6% following a February 2022 voluntary recall and production stoppage at a U.S. infant-formula facility.
- Operating earnings benefited from higher sales volume, particularly COVID-19 rapid tests, and margin initiatives. These benefits were partly offset by the infant-formula recall, inflation in manufacturing and distribution inputs, and higher research and development spending.
- Operating cash flow declined because of greater working-capital investment and substantially higher pension contributions, partly offset by higher operating earnings and lower cash taxes.
- Accumulated other comprehensive loss increased to $8.474 billion from $8.374 billion at year-end, primarily reflecting foreign-currency translation and derivative losses.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide a clear quantitative full-year earnings or revenue guidance figure.
- Management stated that the duration and impact of the COVID-19 pandemic remain uncertain. Future COVID-19 testing demand may be volatile, creating a risk to the Diagnostics segment’s growth comparisons.
- Abbott could not predict when the U.S. infant-formula facility affected by the recall and production stoppage would restart. The company was working with the FDA on corrective actions, sourcing product from Europe, and increasing production at other U.S. facilities.
- Other net expense for Q1 2022 included $120 million of charges related to the voluntary Nutritional Products recall.
- Abbott faces lawsuits involving certain specialty infant-formula products administered to preterm infants. In April 2022, federal cases were consolidated in the Northern District of Illinois for pretrial purposes.
- Recorded accruals for legal and environmental matters were approximately $40 million, within an estimated possible-loss range of $30 million to $45 million. Management did not expect these matters to have a material adverse effect, although outcomes remain uncertain.
- Abbott recorded $30 million of tax expense from the resolution of prior-year tax positions. Gross unrecognized tax benefits could decrease by approximately $70 million to $80 million within the next twelve months.
- Remaining performance obligations were approximately $3.8 billion in Diagnostics and $428 million in Medical Devices. Abbott expected to recognize approximately 60% within 24 months and approximately 16% during the following 12 months.
- Management stated that disclosure controls and procedures were effective and that no material changes occurred in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether COVID-19 diagnostic testing demand and related revenue decline, stabilize, or remain elevated in subsequent quarters.
- The timing and financial impact of restarting the recalled infant-formula facility, including FDA corrective actions and litigation exposure.
- The sustainability of reported earnings growth after excluding COVID-19 testing revenue and other unusual items.
- Changes in gross margins resulting from inflation, supply-chain costs, product mix, and recall-related charges.
- Working-capital trends, pension contributions, cash generation, and the effect of share repurchases and dividends on liquidity.
- Future debt repayments, interest-rate exposure, foreign-exchange effects, and the fair value of derivative and hedging positions.
- Developments in infant-formula litigation, environmental matters, tax examinations, and other contingencies.